ClariVest Asset Management’s Anika Therapeutics ANIK Stock Holding History

ClariVest Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,900	Closed	-$493K	–	737
2020 Q4	$493K	Sell	10,900 -100	-0.9%	-$3.79K	0.02%	381
2020 Q3	$389K	Sell	11,000 -600	-5%	-$21.7K	0.01%	383
2020 Q2	$437K	Sell	11,600 -600	-5%	-$19.8K	0.01%	424
2020 Q1	$353K	Buy	12,200 +1,000	+9%	+$40.5K	0.01%	430
2019 Q4	$580K	Sell	11,200 -5,200	-32%	-$302K	0.01%	414
2019 Q3	$900K	Hold	16,400	–	–	0.02%	354
2019 Q2	$667K	Buy	+16,400	New	+$598K	0.02%	338
2013 Q4	–	Sell	-2,900	Closed	-$69K	–	592
2013 Q3	$69K	Buy	+2,900	New	+$65.1K	﹤0.01%	430

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

ClariVest Asset Management's ANIK Position: Q1 2021 in Review

ClariVest Asset Management sold out of Anika Therapeutics (ANIK) in Q1 2021, closing a stake of 10,900 shares — an estimated $493K sold.

ClariVest Asset Management first reported a position in ANIK in Q3 2013 and held it in 8 quarters. The position peaked at $900K in Q3 2019. 145 funds tracked by Wall St. Rank hold ANIK as of Q1 2021.

ClariVest Asset Management reported no remaining Anika Therapeutics position as of Q1 2021 after selling out during the quarter.
ClariVest Asset Management sold 10,900 Anika Therapeutics shares in Q1 2021, an estimated $493K.
ClariVest Asset Management first reported a position in Anika Therapeutics in Q3 2013 and held it in 8 quarters.
ClariVest Asset Management's Anika Therapeutics position peaked at $900K in Q3 2019.
145 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2021.

Based on ClariVest Asset Management's 13F filing for Q1 2021, filed 13 May 2021.